Takeda Reports MHLW Approval of Orzeyful (Oveporexton) for Narcolepsy Type 1

Shots: The MHLW has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults Approval was based on extensive data, incl. P-III (FirstLight & RadiantLight) trial assessing Orzeyful (BID) in NT1 pts over 12wks, where FirstLight randomized 168 pts to 3 arms (2mg, 1mg & PBO) & RadiantLight randomized 105 pts to 2 arms (2mg & PBO) Both trials demonstrated improvements across the full spectrum of disease symptoms, incl. excessive daytime sleepiness, cataplexy, and health-related quality of life Ref: Businesswire  |  Image: Takeda  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Takeda Reports MHLW Approval of Orzeyful (Oveporexton) for Narcolepsy Type 1 appeared first on PharmaShots.